BOTHELL, WA, and VANCOUVER, July 25, 2012 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter 2012 financial results will be released on Thursday, August 2, 2012, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide an update on clinical development programs for custirsen and OGX-427.
I didn't hear much in the CC that was new but they said everything is on track: by year-end the SYNERGY trial is due to complete enrollment, the trial of 011 with Cabazitaxel in second-line prostate and with docetaxel in second-line lung cancer are due to begin, they should have data on the P2 trial of 427 in prostate (which has completed enrollment), and they should begin the P2 trial of 427 with Zytiga. The randomized P2 trial of 427 in bladder is progressing but they didn't provide an update on how fast it's enrolling.
They provided a little more detail on the design of the two new P3 trials for 011. And Cormack said a major factor in the TEVA/OGXI decision to make the 011 lung trial a second-line trial using docetaxel is that docetaxel is widely used in second-line lung cancer around the world. In contrast, the agents used in first-line lung cancer are in flux and vary significantly from region to region.
All in all, a positive call I think, and they'll certainly have a lot of trials ongoing in the near future.